Paolo Pevarello

3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization.

Anna Vulpetti, Enrico Pesenti, Ciro Mercurio, 2005, Journal of medicinal chemistry.

Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors.

Anna Vulpetti, E. Casale, A. Vulpetti, 2006, Journal of molecular graphics & modelling.

Fragment-Hopping-Based Discovery of a Novel Chemical Series of Proto-Oncogene PIM-1 Kinase Inhibitors

Obdulia Rabal, Julen Oyarzabal, Joaquin Pastor, 2012, PloS one.

CDK inhibitors in cancer therapy: what is next?

James R Bischoff, M. Barbacid, M. Malumbres, 2008, Trends in pharmacological sciences.

An analysis of the binding modes of ATP-competitive CDK2 inhibitors as revealed by X-ray structures of protein-inhibitor complexes.

Anna Vulpetti, A. Vulpetti, P. Pevarello, 2005, Current medicinal chemistry. Anti-cancer agents.

Benzodipyrazoles: a new class of potent CDK2 inhibitors.

Anna Vulpetti, Alexander Cameron, Roberto D'Alessio, 2005, Bioorganic & medicinal chemistry letters.

3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding.

Anna Vulpetti, Antonella Isacchi, Enrico Pesenti, 2004, Journal of medicinal chemistry.

3-Kinases Selective Inhibitors of Phosphoinositide andNuclear Translocation Identifies Potent Chemical Interrogation of FOXO 3 a Mechanisms of Signal Transduction :

Obdulia Rabal, Julen Oyarzabal, Amancio Carnero, 2009 .

NMR-Based screening with competition water-ligand observed via gradient spectroscopy experiments: detection of high-affinity ligands.

Stefan Knapp, Marina Veronesi, Claudio Dalvit, 2002, Journal of medicinal chemistry.